Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

The impact of direct‐acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA‐based treatment. Patients (260) were enroll...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2020-07, Vol.27 (7), p.690-698
Main Authors: Knop, Viola, Mauss, Stefan, Goeser, Tobias, Geier, Andreas, Zimmermann, Tim, Herzer, Kerstin, Postel, Nils, Friedrich‐Rust, Mireen, Hofmann, Wolf Peter, Ende, Katrin, Pathil, Anita, Bauer, Tilman, Zeuzem, Stefan, Berg, Thomas, Cornberg, Markus, Börner, Norbert, Ringelhan, Marc, Klinker, Hartwig, Schlenker, Thorsten, Lutz, Thomas, Heinzow, Hauke, Günther, Rainer, Busch, Heiner, Baumgarten, Axel, Buggisch, Peter, Roessle, Martin, Hüppe, Dietrich, Manns, Michael P., Niederau, Claus, Sarrazin, Christoph, Schirmacher, Peter, Simon, Karl‐Georg, Wedemeyer, Heiner
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Bilirubin
chronic hepatitis C
Chronic infection
direct‐acting antiviral (DAA) treatment
Fibrosis
Hepatitis C
Interferon
Liver
Patients
Platelets
Transaminase
transient elastography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The impact of direct‐acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA‐based treatment. Patients (260) were enrolled in the German Hepatitis C‐Registry (DHC‐R), a national multicentre real‐world cohort. Liver stiffness (LS) was assessed at baseline, end of treatment (EOT) and 24 weeks after EOT (FU24) by TE. Biochemical, virological and clinical data were obtained in parallel. In patients with SVR, there was a significant improvement of LS between baseline (median [range], 8.6 [1.7‐73.5] kPa) and FU24 (7.9 [1.7‐75 kPa]; P 
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13280